vectavir 1% creme
perrigo sverige ab - penciclovir - creme - 1%
niquitgum tropical 2 mg medicinsk tyggegummi
perrigo sverige ab - nicotineresinat - medicinsk tyggegummi - 2 mg
niquitgum tropical 4 mg medicinsk tyggegummi
perrigo sverige ab - nicotineresinat - medicinsk tyggegummi - 4 mg
niquitgum mint 2 mg medicinsk tyggegummi
perrigo sverige ab - nicotineresinat - medicinsk tyggegummi - 2 mg
niquitgum mint 4 mg medicinsk tyggegummi
perrigo sverige ab - nicotineresinat - medicinsk tyggegummi - 4 mg
vectatone 1 % creme
perrigo sverige ab - penciclovir - creme - 1 %
ellaone
laboratoire hra pharma - ulipristal - præception, postcoital - køn hormoner og modulatorer af den genitale system, , nød-prævention - nødprævention indenfor 120 timer (fem dage) af ubeskyttet samleje eller svangerskabsforebyggende svigt.
norlevo 1,5 mg tabletter
laboratoire hra pharma - levonorgestrel - tabletter - 1,5 mg
vildagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, type 2 - narkotika anvendt i diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgængelige data på forskellige kombinationer).
icandra (previously vildagliptin / metformin hydrochloride novartis)
novartis europharm limited - vildagliptin, metformin-hydrochlorid - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgængelige data på forskellige kombinationer).